Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new automated insulin delivery system called twiist significantly improved blood sugar control in adults with insulin-treated type 2 diabetes over just 13 weeks. A1c levels dropped by 0.7% and time in healthy glucose range jumped 16 percentage points — with zero severe hypoglycemia events. Patients also reported sleeping better and feeling more satisfied compared to their previous insulin methods.
A 13-week clinical trial published in Diabetes Care found that the twiist automated insulin delivery (AID) system — already FDA-cleared for type 1 diabetes — delivered meaningful glycemic improvements in adults with insulin-treated type 2 diabetes (T2D). The study enrolled 307 adults aged 19–85 across a range of prior insulin regimens, including basal-bolus injections, open-loop pumps, and basal insulin alone.
The results were striking: average A1c fell from 8.1% to 7.4%, and time spent in the healthy glucose range (70–180 mg/dL) climbed from 57% to 73%. Notably, the system worked even for patients already on GLP-1 receptor agonists or SGLT2 inhibitors, suggesting AID can stack on top of existing therapies. Patients also reported better sleep and higher satisfaction with twiist than with their previous insulin delivery methods.
By the Numbers:
Why it matters: With type 2 diabetes affecting hundreds of millions globally, tools that automate insulin delivery and reduce the burden of self-management could be transformative — especially for patients who struggle to maintain glycemic control on conventional regimens.
